Clinical Scorecard: MRI Characteristics of CNS Large B-cell Lymphoma: An Analysis of Susceptibility and T2*-weighted Imaging in a Large Cohort from a Single Center

At a Glance

Key Highlights

• DLBCL is the most prevalent primary CNS lymphoma subtype, classified as immune-privileged site large B-cell lymphoma (IP-LBCL).
• Susceptibility effects (SE) on MRI, previously considered rare in IP-LBCL, may be present in up to 50% of cases.
• Hemorrhage and necrosis are characteristic in immunodeficiency-associated CNS lymphomas, with variable MRI patterns including punctate, linear, confluent, conglomerate, and ring-like SE.

Guideline-Based Recommendations

Diagnosis

• Use cranial MRI with T2*-weighted and susceptibility-weighted imaging sequences to identify susceptibility effects within CNS lymphoma lesions.
• Avoid corticosteroid administration prior to biopsy to preserve diagnostic accuracy.
• Classify lesions based on MRI morphological patterns (solid, necrotic, diffuse, enhancing) and SE patterns for differential diagnosis.

Management

• Consider immune status (immunodeficiency, autoimmune, post-transplantation) in clinical evaluation and treatment planning.
• Recognize that secondary CNS lymphoma (SCNSL) often shows parenchymal involvement distinct from leptomeningeal patterns in other lymphoma subtypes.

Monitoring & Follow-up

• Perform serial MRI including susceptibility-based sequences to monitor lesion evolution and treatment response.
• Use consensus neuroradiological review to assess changes in susceptibility effects and lesion morphology.

Risks

• Corticosteroid use prior to biopsy may obscure histopathological diagnosis.
• Misinterpretation of susceptibility effects may lead to diagnostic confusion with malignant gliomas or other hemorrhagic lesions.

Patient & Prescribing Data

Adults with primary or secondary CNS DLBCL undergoing MRI evaluation

MRI findings of susceptibility effects and lesion morphology can guide biopsy timing and immunotherapy considerations; corticosteroid exposure prior to imaging should be minimized.

Clinical Best Practices

• Ensure MRI protocols include high-quality T2*-weighted and susceptibility-weighted imaging sequences.
• Conduct independent and consensus neuroradiological readings to accurately identify and categorize susceptibility effects.
• Integrate MRI findings with clinical immune status and histopathology for comprehensive diagnosis.
• Avoid corticosteroids before biopsy to maintain diagnostic yield.
• Recognize the heterogeneity of MRI presentations in CNS DLBCL to differentiate from gliomas and other CNS pathologies.

References

• WHO Classification of Hematolymphoid Tumors, 5th edition
• Neuroradiological features of CNS lymphoma and corticosteroid impact
• MRI susceptibility effects in CNS lymphoma
• Immunodeficiency-associated CNS lymphoma characteristics
• DLBCL secondary CNS lymphoma imaging patterns